RecruitingNot ApplicableNCT06894875

Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance

Examining the Safety and Tolerability of Lentil Protein Hydrolysate in Healthy Males and Females Whilst Exploring the Effects of a Dose Range on Blood Pressure Control and Vascular Function and Exercise Performance


Sponsor

Nuritas Ltd

Enrollment

48 participants

Start Date

Jun 24, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Examining the safety and tolerability of Lentil Protein Hydrolysate in healthy males and females whilst exploring the effects of a dose range on blood pressure control and vascular function and exercise performance


Eligibility

Min Age: 18 YearsMax Age: 45 Years

Inclusion Criteria8

  • Willing to provide written and dated informed consent to participate in the study.
  • Willing and able to comply with the protocol.
  • Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor.
  • Male or female between 18 and 45 years of age (18.5 kg/m2 ≥ BMI \< 30 kg/m2).
  • Comply with ACSM guidelines for physical activity.
  • Have not participated in a clinical trial within the past month and agree to not participate in another clinical trial during the study period.
  • Agree to not significantly alter diet or exercise routine during the trial period.
  • Willing to wear a wearable device continuously for the duration of the study

Exclusion Criteria11

  • Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products.
  • Subjects with a history of alcohol and/or other drug abuse in the past year.
  • Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982).
  • Consuming \>14 alcoholic drinks per week or \> 2 drinks/day in the 48 hours preceding a clinic visit.
  • Active smokers, nicotine use or vaping
  • Subjects suffering from a sleep disorder and/or who have a known history of (or was being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might put the subject at risk and/or confounded the results of the study.
  • Subjects with a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.).
  • Subjects with an elevated resting heart rate (\>100 bpm) or blood pressure (systolic BP \>140 mmHg or diastolic BP \>90 mmHg).
  • Pregnant or lactating women
  • Presentation of orthostatic hypotension during the screening and familiarisation study visit
  • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTLentil protein hydrolysate

Plant protein hydrolysate

DIETARY_SUPPLEMENTPlacebo MCC micro-crystalline cellulose

Placebo MCC micro-crystalline cellulose


Locations(1)

Baker Heart and Diabetes Institute

Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06894875


Related Trials